GBGrażyna Bochenek

Grażyna Bochenek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Grażyna Bochenek has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The prevalence of chronic obstructive pulmonary disease in hospitalized tobacco smokers with peripheral artery disease

    by Marek Kaszuba, Jolanta Kościelniak, Agnieszka Śliwka, Rafał Piliński, Grażyna Bochenek, Paweł Maga, Roman Nowobilski

    Summary: Background: Peripheral artery disease (PAD) and chronic obstructive pulmonary disease (COPD) are inflammatory diseases. These two entities often co-exist, but little is known about the prevalence of this phenomenon in patients with PAD. The objectives of this prospective cross-sectional study were to determine the prevalence of COPD in patients with PAD and to assess the frequency of COPD underdiagnosis in this group of patients. Patients and methods: Consecutive patients admitted to angiology department were evaluated. Measurements of ankle-brachial and toe-brachial index as well as peripheral arteriography were performed in all participants to confirm PAD. In tobacco smokers with PAD spirometry was performed to identified patients with COPD. Clinical information was obtained from the patients on the basis of questionnaires. Results: Eighty-eight out of 300 consecutive patients were included and assessed. COPD was diagnosed in 33 (37.5%) hospitalized smokers with PAD. COPD has not previously been diagnosed in 28 (84.8%) patients who met the criteria of the disease. Conclusions: There was high prevalence of COPD among tobacco smokers hospitalized in the angiology department. Most of them had never had spirometry performed before. The underdiagnosis rate is relatively high; therefore, all patients with PAD who smoke tobacco should have a spirometry performed, as a screening for COPD.


  • NLRP1 Is a Prominent Inflammasome Sensor Found in Bronchial Epithelial Cells in Asthma and Can Be Activated by Rhinovirus A16

    by Anet Laanesoo, Mariel Mäe, Anu Remm, Sebastian L. Johnston, Alan Altraja, Grazyna Bochenek, Bogdan Jakiela, Ana Rebane

    Background: Asthma exacerbations are frequently triggered by human rhinoviruses (RVs). Among other pro‐inflammatory responses, RV infection of airway epithelium promotes the activation of the inflammasome pathway, the role of which in asthma exacerbations and disease progression is still poorly understood.Methods: Bronchial brushing or biopsy specimens were collected from asthma patients and control subjects. Functional experiments were performed in cultured human bronchial epithelial cells (HBECs) using RV‐A16, poly(I:C), and siRNA transfection. Gene expression was analysed by RNA‐sequencing, RT‐qPCR, immunofluorescence, western blot or ELISA. Caspase‐1 activity was evaluated using FAM‐FLICA assay.Results: The expression of NLRP1 was found to be the highest compared to other inflammasome sensors tested in brushed bronchial epithelium samples from asthma patients and control individuals, as well as in cultured primary HBECs. Additionally, we observed increased expression of CASP1 mRNA in bronchial epithelial cells from patients with neutrophilic asthma compared to those with paucigranulocytic and eosinophilic phenotypes. Changes in the expression of inflammasome pathway genes caused by RV‐A16 infection were similar in HBEC cultures from asthma patients and controls, except for IL‐1β, which showed increased response, and PYCARD, which exhibited decreased change in cells derived from asthma patients. Silencing of NLRP1 expression with siRNAs impeded RV‐A16‐induced activation of the inflammasome but had no effect on poly(I:C)‐induced secretion of IL‐1β and IL‐18.Conclusion: NLRP1 is highly expressed inflammasome sensor in both healthy and asthmatic bronchial epithelium and can be activated by RV‐A16. RV‐induced changes in the expression of inflammasome pathway genes suggest that there may be differences in HBECs derived from asthma patients, which may depend on the prevailing immunological phenotype of the disease.


  • Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease

    by Bogdan Jakiela, Jerzy Soja, Krzysztof Sladek, Marek Przybyszowski, Hanna Plutecka, Anna Gielicz, Ana Rebane, Grazyna Bochenek


  • Late Breaking Abstract - Overestimation of asthma control and misperception of short-acting ß2-agonists (SABA) use among physicians in Poland

    by Radosław Gawlik, Grażyna Bochenek, Dorota Brzostek, Wojciech Barg, Grzegorz Brożek, Piotr Dąbrowiecki, Andrzej Dąbrowski, Rafał Dobek, Aleksandra Kucharczyk, Maciej Kupczyk, et al.

    Background: Poland does not currently have a national asthma management policy. Although the global GINA guidelines are regularly translated, they may be adopted differently by physicians. Objective: To investigate, if the real-life assessment of asthma control in Poland meets global management standards. Methods: In total, 70 alergists, 80 pulmonologists and 103 GPs participated in the study. All physicians responded to a qualitative questionnaire and delivered diaries (assessment and decisions) of the 10 consecutive asthma patients. The level of asthma control assessed subjectively by the physicians was matched with the patient-reported symptoms according to the GINA guidelines. We also asked physicians about the frequency of short-acting ß2-agonists (SABA) use as a sign of poor asthma control. Results: Data obtained from 253 physicians and 2,482 patients showed, that only 59.1% allergists, 44.1% pulmonologists and 44.1% GPs correctly assessed the level of asthma control according to the GINA guidelines (p=0.05, chi²-test). In terms of the GINA guidelines for SABA consumption, only 27% of allergists, 15% pulmonologists and 12% GPs correctly stated the use 1-2 times per week was indicative of controlled asthma. Meanwhile, 41% allergists, 62% pulmonologists and 59% GPs incorrectly assumed the use of 3 or more SABA canisters per year was a sign of controlled asthma. Conclusions: We found low adoption of the GINA guidelines in terms of the assessment of asthma control in Poland, especially regarding SABA overuse. Incorrect assessment of asthma control may lead to sub-optimal treatment decisions.


  • Open Access

    Predictors of excessive short-acting beta2-agonist use and asthma exacerbations: a retrospective analysis of a Polish prescription database

    by Maciej Kupczyk, Wojciech Barg, Grażyna Bochenek, Grzegorz Brożek, Dorota Brzostek, Piotr Dąbrowiecki, Andrzej Dąbrowski, Rafał Dobek, Radosław Gawlik, Aleksandra Kucharczyk, et al.

    Background: Excessive use of short-acting beta2-agonists (SABA) is indicative of poor asthma control, and may increase the risk of exacerbations and asthma-related fatalities. Objectives: This study aimed to determine the factors associated with frequent (≥3 SABA canisters/year) and excessive (≥12 SABA canisters/year) SABA use in a real-life setting and indentify any predictors of asthma exacerbations. Methods: Purchase records from a 1-year period (2018) were retrieved from the nationwide prescription database comprising 5,600 pharmacies across Poland. Of the 91,673 patients (aged 18-64 years) included, there were 5,202 (5.7%) on SABA-only treatment, 5,961 (6.5%) on inhaled corticosteroid (ICS)-mono treatment, and 73,313 (80%) on combined ICS/long-acting beta2 agonist (LABA) therapy. Results: SABA use was most frequent among patients who did not use ICS. Older age (relative risk [RR] 1.06, p<0,001) was associated with a higher risk of excessive SABA use; the risk was lower in women (RR, 0.63, p<0,001), in those under secondary care (RR, 0.60, p<0,001), and in those on ICS with (RR, 0.52, p<0,001) or without (RR, 0.41, p<0,001) LABA therapy. Excessive SABA use was the strongest predictor of asthma exacerbations (RR, 3.23, p<0,001); however older patients (RR, 1.34, p<0,001), women (RR, 1.14, p=0,001), those under secondary care (RR, 1.19, p 100,000 inhabitants (RR, 1.24, p<0,001) were also at risk. Conclusion: Excessive SABA use is most frequent in those who do not use ICS and triples the risk of asthma exacerbation.

  • Effect of combined inhaled corticosteroid-formoterol therapy on short-acting beta2-agonist use in Poland: a retrospective analysis of pharmacy reports

    by Rafał Dobek, Wojciech Barg, Grażyna Bochenek, Grzegorz Brożek, Dorota Brzostek, Piotr Dąbrowiecki, Andrzej Dąbrowski, Radosław Gawlik, Aleksandra Kucharczyk, Izabela Kuprys-Lipińska, et al.

    Background: The Global Initiative for Asthma (GINA) 2019 report proposed novel approaches to asthma management, including using combined inhaled corticosteroid-formoterol (ICS/FOR) on an as-needed basis. Patients on ICS/FOR therapy should not require additional short-acting beta2-agonists (SABA) administration. Objective: This study aimed to compare SABA use in patients treated with ICS/FOR to those treated with ICS/salmeterol (ICS/SAL). Methods: We analysed prescription database records from 5,712 pharmacies in Poland, providing information on asthma medications collected by 111,186 patients (aged 12-64 years) (with at least one prescription within six months) in 2018. We included 55,983 patients: 23,375 on ICS/SAL and 32,608 on ICS/FOR. There were 4,248 children (aged 12-17 years), and 51,935 adults (aged 18-64 years). Results: SABA prescriptions were 10% lower in those on ICS/FOR compared to those on ICS/SAL. Meanwhile, the number of prescriptions and total dose of oral corticosteroids (OCS) were similar for patients in ICS/FOR and ICS/SAL. Logistic regression analysis showed the risk of SABA use was 22% lower in those on ICS/FOR than on ICS/SAL (relative risk [RR], 0.78; p<0,001). In adults, the risk of SABA use was also lower in younger patients (RR, 0.93, p<0,001) and men (RR, 1.03, p<0,001). In all subjects, the risk of OCS use was similar for those on ICS/FOR and ICS/SAL, and it was not age-related. Conclusions: Combined ICS/FOR therapy lowers the risk of SABA use in Poland, which supports the new GINA recommendations for asthma management.

  • The comparison between pulmonary rehabilitation with music therapy and pulmonary rehabilitation alone on respiratory drive, cortisol level and asthma control in patients hospitalized with asthma exacerbation

    by Agnieszka Śliwka, Marek Kaszuba, Rafal Piliński, Magdalena Pieniążek, Magdalena Batkiewicz, Karolina Marciniak, Grażyna Bochenek, Roman Nowobilski

    Introduction: Much emphasis is being placed on the role of music therapy as an easy-to-use, non-invasive and relatively cheap method of asthma treatment. The objective of this interventional double-blinded randomised controlled trial was to assess whether music therapy, as a complementary modality to pulmonary rehabilitation, can help to improve respiratory drive, asthma control and quality of life in patients with asthma exacerbation. Methods: Hospitalized patients with asthma exacerbation enrolled in the study were randomly assigned to experimental (music therapy) or control (popular science programme) group. Both groups during hospitalization received standard pharmacotherapy accompanied by respiratory physiotherapy. Respiratory drive, asthma control, quality of life and serum cortisol in all participants were assessed at the beginning and at the end of their hospitalizations. Results: The experimental group consisted of 39 asthmatics and 34 subjects with asthma were assigned to the control group. During the hospitalisation, the levels of the inspiratory occlusion pressure for the first 0.1 second of inspiration (P0.1) decreased (p = 0.004) and the maximum P0.1 increased (p = 0.041) only in the experimental group. The serum cortisol level decreased in both groups (p = 0.001). The changes in asthma control and quality of life did not reach significant levels in either subject group. Conclusion: Passive music therapy and its effects on the mental state of patients seem to improve the efficiency of the respiratory system. The results of this experimental study demonstrate that a complementary music therapy has beneficial effects on the treatment of asthma exacerbations in adults.


  • Late Breaking Abstract - Patterns of inhaled corticosteroid-formoterol prescriptions in Poland

    by Rafał Dobek, Wojciech Barg, Grażyna Bochenek, Grzegorz Brożek, Dorota Brzostek, Piotr Dąbrowiecki, Andrzej Dąbrowski, Radosław Gawlik, Aleksandra Kucharczyk, Maciej Kupczyk, et al.

    Background: The Global Initiative for Asthma (GINA) 2019 report proposed novel approaches to asthma management, including using combined inhaled corticosteroid-formoterol (ICS/FOR) on an as-needed basis. This regimen provides the patient with ICS whenever reliever medication is used. Objective: This study aimed to analyze patterns of ICS/FOR prescriptions in a large group of adolescent and adult patients with asthma in Poland. Methods: We analyzed prescription database records from 5,600 pharmacies in Poland, providing information on asthma medications collected by 146,845 patients (with at least one prescription within six months) in 2018. Results: Combined ICS/ long-acting beta2-agonist (LABA) were collected by 69,497 (48%) patients, of which 28,956 (20% of ICS/LABA users) also received short-acting beta2-agonists (SABA). ICS/FOR together with SABA were collected by 10,304 (15% of all ICS/LABA) and without SABA by 18,417 (26.5% of all ICS/LABA) patients, respectively. Among patients prescribed low-dose ICS/FOR for maintenance and reliever therapy, some 6,725 (9.6% of all ICS/LABA) received SABA. Almost 1/3 of low-dose ICS/FOR patients collected fewer than four canisters of these drugs per year. Conclusions: In a large population of Polish patients with asthma, inappropriate use of SABA is common among those using low-dose ICS/FOR as maintenance and reliever therapy. ICS/FOR refill rates are low for some patients, suggesting as-needed use rather than regular maintenance as prescribed.


  • The Comorbidity of Chronic Obstructive Pulmonary Disease and Peripheral Artery Disease – A Systematic Review

    by Marek Kaszuba, Agnieszka Śliwka, Rafał Piliński, Jolanta Kościelniak, Paweł Maga, Grażyna Bochenek, Roman Nowobilski

    The comorbidity of peripheral arterial disease (PAD) and chronic obstructive pulmonary disease (COPD) is obvious from a clinical point of view, especially as smoking is an important risk factor for both. Another factor connecting these two clinical conditions is chronic inflammation, which plays a crucial role in their pathophysiology. The aim of this study was to present the prevalence of COPD in patients with PAD, as well as the prevalence of PAD in COPD patients confirmed in all patients by two reliable methods: spirometry and ankle-brachial index (ABI), respectively. The MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews were searched to identify the potentially eligible publications from the previous 10 years. The published characteristics of different PAD and COPD populations were analyzed. A database search identified 894 records. Reliable criteria of both COPD and PAD diagnosis were used only in seven publications. The prevalence of PAD among patients with COPD ranged from 8.5 to 81.4%. The severity of the disease and the exclusion of nonsmokers or symptomatic patients from the analyses were important factors affecting this parameter. The prevalence of COPD in patients with PAD was measured reliably only in one study and assessed as 27.2%. The comorbidity of COPD and PAD is a relatively common occurrence. There are very few publications addressing this issue based on reliable diagnostic criteria, especially in the field of PAD. In the case of COPD and PAD patients, spirometry and ABI measurements are worth considering as noninvasive screening tests for COPD and PAD, respectively.


  • Diagnostic Accuracy of Urinary LTE4 Measurement to Predict Aspirin-Exacerbated Respiratory Disease in Patients with Asthma

    by Grazyna Bochenek, Tomasz Stachura, Krystyna Szafraniec, Hanna Plutecka, Marek Sanak, Ewa Nizankowska-Mogilnicka, Krzysztof Sladek